1. What Is the Chronic Pain Market?
The Chronic Pain Market covers the pharmacological and non-pharmacological treatments for the persistent pain lasting over 3 months that affects an estimated 20 percent of adults globally. The conditions include the chronic low back pain, the fibromyalgia, the osteoarthritis pain, the chronic widespread pain, and the chronic postsurgical pain. These arise from different mechanisms of central sensitisation, peripheral inflammation, and psychological factors that the biopsychosocial pain model recognises as the multidimensional contributors to the chronic pain experience. Chronic pain treatment combines the pharmacological approaches including the NSAIDs, the SNRIs, the gabapentinoids, and the opioids with the non-pharmacological approaches. The non-pharmacological approaches include the physical therapy, the cognitive-behavioural therapy, the pain psychology, and the interventional procedures that the multimodal pain management programme provides. The chronic pain patient whose complex pain experience requires the comprehensive approach cannot be served by pharmacological treatment alone. The chronic pain market is being advanced by the nerve growth factor antibody tanezumab that the FDA deferred approval for citing the joint destruction risk. The monoclonal antibody fasinumab that the arthritis pain NGF clinical trials demonstrated is highly effective for the pain relief at the cost of the safety monitoring requirement. The joint safety concerns impose the long-term joint safety data requirement on the NGF antibody class that the regulatory agencies require to accompany the approval application.
2. Chronic Pain Market Size & Forecast
3. Emerging Technologies
- Fasinumab NGF antibody Phase III OA chronic pain trial demonstrated 30 to 40 percent pain reduction versus the NSAID comparator in the osteoarthritis chronic pain population. The clinical efficacy of the NGF pathway is established for the chronic musculoskeletal pain. The fast-progressing osteoarthritis signal that occurred in 1 to 3 percent of the treated patients has delayed the regulatory approval pending the longer-term joint safety data.
- Duloxetine SNRI dual norepinephrine and serotonin reuptake inhibition for the chronic musculoskeletal pain of the fibromyalgia, the osteoarthritis, and the chronic low back pain demonstrated the 30 percent pain reduction. The central sensitisation modulation works through the descending inhibitory pain pathway that the norepinephrine and serotonin reuptake inhibition strengthens. The non-opioid central analgesic mechanism serves the chronic musculoskeletal pain.
- Multidisciplinary pain programme combines the pharmacological pain management with the cognitive-behavioural therapy that addresses the pain catastrophising and the fear-avoidance beliefs. The physical deconditioning rehabilitation and the occupational therapy return the chronic pain patient to the function and the work. The progressive disability from untreated chronic pain removes the function that the multidisciplinary programme restores beyond what pharmacological treatment alone sustains.
- Low-dose naltrexone for the fibromyalgia and the chronic neuroinflammatory pain conditions works through the TLR4 receptor modulation and the microglial activation reduction at the naltrexone dose below the opioid antagonism threshold. The repurposed drug approach is being investigated for the chronic pain conditions. The neuroimmune mechanism contributes to the central sensitisation that the low-dose naltrexone addresses.
Similar technologies are also transforming adjacent markets. Learn more in our Neuropathic Pain Market.
4. Key Market Opportunity
Meaningful upside in the Chronic Pain market is suzetrigine expansion into chronic pain indications, where the approved acute pain indication may extend to chronic pain conditions through additional clinical trials. Companies with Nav1.8 inhibitor platforms capture this novel non-opioid chronic pain category. Additional momentum is centered on next-generation chronic pain mechanisms beyond NSAIDs and opioids. As suzetrigine chronic pain studies advance and novel mechanism development matures, the addressable opportunity is evolving from NSAID and opioid-dominant management toward novel non-opioid chronic pain mechanisms.
5. Top Companies in the Chronic Pain Market
The following organisations hold leading positions in the Chronic Pain Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Pfizer
- Purdue Pharma
- Eli Lilly
- Sanofi
- Sun Pharma
- Teva Pharmaceutical
- Endo Pharmaceuticals
- Mallinckrodt
- Vertex Pharmaceuticals
- AbbVie
- Heron Therapeutics
- Collegium Pharmaceutical
- Pacira BioSciences
- Esteve
- Reckitt Benckiser
6. Market Segmentation
The Chronic Pain Market is analysed across 3 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | NSAIDOpioidAnti-NGFSodium ChannelCannabinoidGabapentinoid |
| By Indication | Chronic BackOsteoarthritisNeuropathicFibromyalgiaCancer Pain |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Chronic Pain Market trajectory over the forecast period:
Fasinumab NGF Antibody 30 to 40 Percent OA Pain Reduction Versus NSAID With 1 to 3 Percent Quickly Progressive OA Safety Signal Illustrates the Efficacy-Safety Trade-Off That Has Delayed NGF Antibody Approval While the Joint Destruction Risk Monitoring Data Accumulate.Vertex Pharmaceuticals's suzetrigine Journavx demonstrated superior pain reduction versus placebo in two Phase 3 acute pain trials and earned January 2025 FDA approval as the first new analgesic mechanism approval since pregabalin in 2004, positioned for expansion into chronic neuropathic pain where unmet need substantially exceeds the acute pain setting. The NaV1.8 channel's restriction to peripheral sensory neurons enables pain-selective sodium channel inhibition without cardiac or CNS sodium channel blockade that limits local anaesthetics, creating a clean pharmacological profile appropriate for chronic daily dosing. Vertex's chronic pain development programme for suzetrigine covers painful diabetic neuropathy, small-fibre neuropathy, and lumbosacral radiculopathy in Phase 2-3 trials that will determine whether the acute pain approval translates into the highest-volume chronic pain indications.
Duloxetine SNRI Descending Inhibitory Pain Pathway Modulation Achieving 30 Percent Chronic Low Back Pain and Fibromyalgia Reduction Has Established the Non-Opioid Central Analgesic That Addresses the Central Sensitisation Component That Peripheral NSAIDs and Opioids Cannot Specifically Target.Assertio's tapentadol Nucynta extended-release demonstrated equivalent chronic pain control to oxycodone CR with significantly fewer opioid-class gastrointestinal adverse events in OPANA comparative trials, reflecting the reduced mu-opioid component required when norepinephrine reuptake inhibition contributes to analgesia through descending pain-modulation enhancement. The norepinephrine mechanism is particularly relevant in neuropathic pain where central sensitisation and deficient inhibitory pain control contribute to chronification, making tapentadol mechanistically well-suited to the neuropathic-nociceptive mixed pain syndromes that represent the largest chronic pain population. Abuse deterrent extended-release formulations of tapentadol and the general trend toward abuse-deterrent opioid formulations reflect the regulatory and societal imperative to reduce prescription opioid diversion in the context of the ongoing opioid epidemic.
Multidisciplinary Pain Programme Combining CBT Pain Catastrophising Treatment With Physical Rehabilitation and Occupational Therapy Has Demonstrated the Functional Restoration Outcomes That Pharmacological Treatment Alone Does Not Sustain for the Complex Central Sensitisation Chronic Pain Patient.Focused ultrasound from InSightec ExAblate Neuro and Insightec system delivered transcranially at low intensity can modulate thalamic and anterior cingulate cortex activity involved in pain processing, achieving analgesic effects in chronic pain conditions including fibromyalgia and chronic low back pain in Phase 2 studies. The non-invasive and spatially targeted nature of transcranial focused ultrasound distinguishes it from spinal cord stimulation implants that require surgery and from non-focused transcranial modalities that lack the spatial precision to target specific subcortical pain-processing nodes. Regulatory pathway for non-invasive brain stimulation pain devices requires clinical evidence of superiority over sham stimulation in controlled trials, and the FOCUS chronic pain programme from InSightec is generating the Phase 3 dataset intended to support FDA de-novo clearance for this indication.
For related market intelligence, see the Pharmaceutical Market.
8. Segmental Analysis
By drug class, the opioid analgesic segment dominated the Chronic Pain Market in 2025, as established and abuse-deterrent formulations anchored management of severe chronic pain despite tightening prescribing controls, generating the largest treatment volume in the indication.
By indication, the postsurgical and musculoskeletal pain segment is projected to register the highest growth rate through 2034, as Vertex Pharmaceuticals's Journavx selective sodium-channel inhibitor and other non-opioid mechanisms offer effective analgesia without addiction risk, addressing the central clinical and commercial priority of opioid-sparing pain management.
9. Regional Analysis
Regional demand patterns across the Chronic Pain Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Chronic Pain Market in 2025, accounting for approximately 48% of global revenue, attributed to US prescribing volume for analgesics and the concentration of suzetrigine and novel non-opioid analgesic development. Moreover, post-opioid-crisis non-opioid prescribing emphasis is most advanced in the US. In addition, Vertex commercial launch of suzetrigine is concentrated in North America. Regional dominance is due to this combination of prescribing scale and novel mechanism leadership.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Chronic Pain Market through 2034, driven by the large chronic pain patient population in China, India, and Southeast Asia and expanding access to non-opioid analgesics and chronic pain management. The region is also witnessing suzetrigine and novel mechanism adoption growing. Moreover, NSAID prescribing volume sustains baseline demand. The combination of these demand drivers and patient scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Chronic Pain Market was valued at USD 33.34 Bn in 2025 and is projected to reach USD 48.28 Bn by 2034, growing at a CAGR of 4.2% over the 2026–2034 forecast period.
The Chronic Pain Market is projected to grow at a CAGR of 4.2% from 2026 to 2034.
North America dominated the Chronic Pain Market in 2025, accounting for approximately 48% of global revenue, attributed to US prescribing volume for analgesics and the concentration of suzetrigine and novel non-opioid analgesic development.
The leading companies in the Chronic Pain Market include Pfizer, Purdue Pharma, Eli Lilly, Sanofi, Sun Pharma, Teva Pharmaceutical, Endo Pharmaceuticals, Mallinckrodt, Vertex Pharmaceuticals, AbbVie, Heron Therapeutics, Collegium Pharmaceutical, Pacira BioSciences, Esteve, Reckitt Benckiser.
Fasinumab ngf antibody 30 to 40 percent oa pain reduction versus nsaid with 1 to 3 percent quickly progressive oa safety signal illustrates the efficacy-safety trade-off that has delayed ngf antibody approval while the joint destruction risk monitoring data accumulate.
By drug class, the opioid analgesic segment dominated the Chronic Pain Market in 2025, as established and abuse-deterrent formulations anchored management of severe chronic pain despite tightening prescribing controls, generating the largest treatment volume in the indication.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.